Skip to main content

Table 2 Phase 1 and early phase 1 CAR-T trials for RRMM, as of December 31, 2020, with study start date after January 1, 2019

From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Antigen

Product name* (NCT)

Study sponsor

Estimated enrollment

Country

Single-target CAR-T cells

    

BCMA

IM21 (NCT04537442)

Beijing Immunochina Medical Science and Technology

10

China

BCMA

CT053 (NCT03975907)

Carsgen

62

China

BCMA

NCT04271644, NCT04272151

Chongqing Precision Biotech

80

40

China

BCMA

C-CAR088 (NCT03815383)

First Affiliated Hospital with Nanjing Medical University

12

China

BCMA

NCT04626752

Hebei Senlang Biotechnology

50

China

BCMA

C-CAR088 (NCT03751293)

Hebei Yanda Ludaopei Hospital

10

China

BCMA

NCT04601935

Nanjing Legend Biotech

34

China

BCMA

C-CAR088 (NCT04295018)

Peking Union Medical College Hospital

10

China

BCMA

NCT04186052

PersonGen Bio (Suzhou)

10

China

BCMA

C-CAR088 (NCT04322292)

Tianjing Institute of Hematology and Blood Diseases

10

China

BCMA

NCT04637269

Xinqiao Hospital of Chongqing

16

China

BCMA

CARTBCMA ARI0002h (NCT04309981)

Institut d'Investigacions Biomèdiques August Pi i Sunyer

36

Spain

BCMA

NCT04155749

Arcelix

12

United States

BCMA

CT053 (NCT03915184)

Carsgen

70

United States, Canada

BCMA

Descartes-11 (NCT03994705)

Cartesian

18

United States

BCMA

CYAD-211 (NCT04613557)

Celyad Oncology

12

United States, Belgium

BCMA

CC-98633 (NCT04394650)

Juno/Celgene

80

United States

BCMA

PHE885 (NCT04318327)

Novartis

16

United States

CD4

NCT04162340

iCell Gene Therapeutics

12

China

CD22

NCT03999697

PersonGen BioTherapeutics (Suzhou)

10

China

CD44

MLM-CAR44.1 (NCT04097301)

MolMed S.p.A

58

Italy

CD138

NCT03672318

University of North Carolina

33

United States

GPRC5D

MCARH109 (NCT04555551)

Memorial Sloan Kettering Medical Center

36

United States

HA-1

MDG1021 (NCT04464889)

Medigene

29

The Netherlands

SLAMF7

NCT04499339

Wuerzburg University Hospital

38

Germany

SLAMF7

NCT03958656

National Cancer Institute

36

United States

TnMUC1

NCT04025216

Tmunity

112

United States

Dual-target CAR-T cells

    

BCMA CD19

NCT04194931

The First Affiliated Hospital of Nanchang University

20

China

BCMA CD19

NCT04162353

iCell Gene Therapeutics

12

China

BCMA CD19

GC012F (NCT04236011)

Shanghai Changzheng Hospital

15

China

BCMA CD19

NCT04280328

Xian Xijing Hospital

18

China

BCMA CD19

NCT04603872

Zhejiang University

120

China

Universal CAR-T cells

    

BCMA

ALLO-715 (NCT04093596)

Allogene

90

United States

BCMA

CTX120 (NCT04244656)

CRISPR Therapeutics

80

United States, Australia, Spain

BCMA

PBCAR269A (NCT04171843)

Precision BioSciences

48

United States

Other

    

Anti-BCMA CAR-NK cells

NCT03940833

Asclepius Technology (Suzhou)

20

China

PD-L1 plus other antigen

NCT04191941

Timmune Biotech

9

China

CD34 + enriched hematopoietic progenitor cells expressing interferon-ɑ2

Temferon (NCT03875495)

Genenta

9

Italy

CD8 + T-cells expressing WT1, CD138, NY-ESO-1, and CS1

NEXI-002 (NCT04505813)

NexImmune

22

United States

  1. * In cases where no unique product name was given, only the NCT number is listed